Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2023-05-25 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
2022 年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2022 annual equity distribution (dividend) by 安徽峆一药业股份有限公司. It details the dividend amount, payment dates, tax treatment, and record dates. It references the shareholders' meeting approval but does not contain financial statements or comprehensive financial performance data. The document length is short (1203 characters) and it is clearly an announcement of dividend distribution details rather than a full annual report or financial statement. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2023-05-25 Chinese
2022年年度股东大会决议公告
AGM Information Classification · 95% confidence The document is titled as a 2022 Annual General Meeting (AGM) resolution announcement for Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the proceedings and outcomes of the AGM, including approval of reports and proposals, but does not contain the full annual report or financial statements themselves. It is a formal announcement of the AGM resolutions rather than the report or financial data. Therefore, it fits the category of AGM Information (AGM-R). The document length (6378 characters) and detailed meeting content support this classification with high confidence.
2023-05-16 Chinese
上海市锦天城律师事务所关于安徽峆一药业股份有限公司2022年年度股东大会的法律意见书
Regulatory Filings Classification · 46% confidence The document is a legal opinion letter from a law firm regarding the procedural legality and voting results of the company’s 2022 Annual General Meeting. It is not the Annual Report itself, not a proxy solicitation document, nor a direct voting results announcement in the usual concise form. It does not match any specific form category. It is therefore best classified as a general regulatory filing (RNS).
2023-05-16 Chinese
安徽峆一药业股份有限公司投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is titled as an "投资者关系活动记录表" (Investor Relations Activity Record) and describes an "业绩说明会" (performance explanation meeting) held on April 27, 2023, regarding the 2022 annual report. It includes detailed Q&A about the company's 2022 business performance, dividend distribution, fundraising project progress, and other operational details. The document is a transcript or record of an investor presentation event focused on financial results and company strategy. It is not the annual report itself, nor a brief announcement or certification. The content matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. The document length (4756 characters) supports it being a substantive presentation record rather than a short announcement. Therefore, the correct classification is Investor Presentation (IP).
2023-05-07 Chinese
第四届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the review and approval of the company's 2023 first quarter report. It references the actual quarterly report published separately on the official exchange platform, indicating this document is about the meeting decision rather than the report itself. The document is short (963 characters) and serves as an official announcement of the Supervisory Board meeting resolution, not the financial report. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement related to regulatory compliance and internal governance but not a full report or detailed financial disclosure.
2023-04-26 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as "安徽峆一药业股份有限公司 2023 年第一季度报告" which translates to "Anhui X Pharmaceutical Co., Ltd. 2023 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial changes for the period ending March 31, 2023. The report explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the first quarter of 2023. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-26 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.